AU2002347022A1 - Benzimidazols and indols as glucagon receptor antagonists/inverse agonisten - Google Patents
Benzimidazols and indols as glucagon receptor antagonists/inverse agonistenInfo
- Publication number
- AU2002347022A1 AU2002347022A1 AU2002347022A AU2002347022A AU2002347022A1 AU 2002347022 A1 AU2002347022 A1 AU 2002347022A1 AU 2002347022 A AU2002347022 A AU 2002347022A AU 2002347022 A AU2002347022 A AU 2002347022A AU 2002347022 A1 AU2002347022 A1 AU 2002347022A1
- Authority
- AU
- Australia
- Prior art keywords
- benzimidazols
- agonisten
- indols
- inverse
- receptor antagonists
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/08—Radicals containing only hydrogen and carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/10—Radicals substituted by halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/14—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200101925 | 2001-12-20 | ||
| DKPA200101925 | 2001-12-20 | ||
| PCT/DK2002/000832 WO2003053938A1 (en) | 2001-12-20 | 2002-12-10 | Benzimidazols and indols as glucagon receptor antagonists/inverse agonisten |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2002347022A1 true AU2002347022A1 (en) | 2003-07-09 |
Family
ID=8160918
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002347022A Abandoned AU2002347022A1 (en) | 2001-12-20 | 2002-12-10 | Benzimidazols and indols as glucagon receptor antagonists/inverse agonisten |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU2002347022A1 (en) |
| WO (1) | WO2003053938A1 (en) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0203070D0 (en) * | 2002-10-16 | 2002-10-16 | Astrazeneca Ab | Novel compounds |
| WO2004063147A1 (en) * | 2003-01-10 | 2004-07-29 | Novo Nordisk A/S | Salts and solvates of glucagon antagonists |
| CA2513102C (en) | 2003-01-27 | 2011-03-22 | Merck & Co., Inc. | Substituted pyrazoles, compositions containing such compounds and methods of use |
| KR101049348B1 (en) | 2003-05-05 | 2011-07-13 | 톰슨 라이센싱 | Systems and Methods for Blocking Television Signals with Different Multiple Content Ratings |
| SE0301699D0 (en) * | 2003-06-10 | 2003-06-10 | Astrazeneca Ab | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
| SE0301698D0 (en) | 2003-06-10 | 2003-06-10 | Astrazeneca Ab | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
| CA2534649A1 (en) | 2003-08-01 | 2005-02-10 | Genelabs Technologies, Inc. | Bicyclic imidazol derivatives against flaviviridae |
| PL1756064T3 (en) | 2004-06-04 | 2008-11-28 | Merck Sharp & Dohme | Pyrazole derivatives, compositions containing such compounds and methods of use |
| RU2006142552A (en) | 2004-06-16 | 2008-07-27 | Вайет (Us) | AMINO-5,5-DIPHENYLIMIDAZOLONE DERIVATIVES AS B-SECRETASE INHIBITORS |
| CN1997646A (en) | 2004-06-16 | 2007-07-11 | 惠氏公司 | Diphenylimidazopyrimidine and -imidazole amines as inhibitors of beta-secretase |
| CA2573185A1 (en) | 2004-07-14 | 2006-02-23 | Ptc Therapeutics, Inc. | Methods for treating hepatitis c |
| US7781478B2 (en) | 2004-07-14 | 2010-08-24 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| US7772271B2 (en) | 2004-07-14 | 2010-08-10 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| US7868037B2 (en) | 2004-07-14 | 2011-01-11 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| EP1773330B1 (en) | 2004-07-22 | 2010-05-26 | Merck Sharp & Dohme Corp. | Substituted pyrazoles, compositions containing such compounds and methods of use |
| JP2008507518A (en) | 2004-07-22 | 2008-03-13 | ピーティーシー セラピューティクス，インコーポレーテッド | Thienopyridine for treating hepatitis C |
| MX2007004910A (en) * | 2004-10-27 | 2007-06-14 | Hoffmann La Roche | New indole or benzimidazole derivatives. |
| WO2006076284A2 (en) | 2005-01-14 | 2006-07-20 | Wyeth | AMINO-IMIDAZOLONES FOR THE INHIBITION OF ß-SECRETASE |
| EP1844035A1 (en) | 2005-02-01 | 2007-10-17 | Wyeth | Amino-pyridines as inhibitors of beta-secretase |
| KR20070102751A (en) | 2005-02-14 | 2007-10-19 | 와이어쓰 | AZOLYLACYLGUANIDINES AS beta;-SECRETASE INHIBITORS |
| EP1863755A1 (en) | 2005-03-21 | 2007-12-12 | Merck & Co., Inc. | Substituted aryl and heteroaryl derivatives |
| JP2008534593A (en) | 2005-03-30 | 2008-08-28 | メルク エンド カムパニー インコーポレーテッド | Glucagon receptor antagonist compounds, compositions containing such compounds, and methods of use thereof |
| CN101213183A (en) | 2005-06-30 | 2008-07-02 | 惠氏公司 | Amino-5-(6-membered)heteroarylimidazolone compounds and the use thereof for beta-secretase modulation |
| TW200738683A (en) | 2005-06-30 | 2007-10-16 | Wyeth Corp | Amino-5-(5-membered)heteroarylimidazolone compounds and the use thereof for β-secretase modulation |
| JP2009502923A (en) | 2005-07-26 | 2009-01-29 | メルク エンド カムパニー インコーポレーテッド | Method for the synthesis of substituted pyrazoles |
| CA2623245A1 (en) | 2005-09-26 | 2007-04-05 | Wyeth | Amino-5- [4- (difluoromethoxy) phenyl] -5-phenylimidazolone compounds as inhibitors of the beta-secretase (bace) |
| JP2009001495A (en) * | 2005-10-13 | 2009-01-08 | Taisho Pharmaceutical Co Ltd | 2-aryl-benzimidazole-5-carboxamide derivative |
| TW200745031A (en) | 2005-10-13 | 2007-12-16 | Merck & Co Inc | Acyl indoles, compositions containing such compounds and methods of use |
| WO2007062996A1 (en) | 2005-11-30 | 2007-06-07 | F. Hoffmann-La Roche Ag | 3-amino-1-arylpropyl indoles and aza-substituted indoles |
| JP2009517432A (en) | 2005-11-30 | 2009-04-30 | エフ．ホフマン−ラ ロシュ アーゲー | 3-Amino-2-arylpropyl azaindole and uses thereof |
| WO2007100536A1 (en) | 2006-02-24 | 2007-09-07 | Wyeth | DIHYDROSPIRO[DIBENZO[A,D][7]ANNULENE-5,4'-IMIDAZOL] COMPOUNDS FOR THE INHIBITION OF β-SECRETASE |
| EP2001472A2 (en) | 2006-03-23 | 2008-12-17 | Merck and Co., Inc. | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
| JP2009537525A (en) | 2006-05-16 | 2009-10-29 | メルク エンド カムパニー インコーポレーテッド | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
| US7700606B2 (en) | 2006-08-17 | 2010-04-20 | Wyeth Llc | Imidazole amines as inhibitors of β-secretase |
| TW200821284A (en) | 2006-10-03 | 2008-05-16 | Merck & Co Inc | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
| WO2008098244A1 (en) | 2007-02-09 | 2008-08-14 | Metabasis Therapeutics, Inc. | Novel antagonists of the glucagon receptor |
| PE20090617A1 (en) | 2007-03-23 | 2009-05-08 | Wyeth Corp | AMINO-5 - [- 4- (DIFLUOROMETOXI) PHENYL] -5-PHENYLIMIDAZOLONE COMPOUNDS FOR THE INHIBITION OF -SECRETASE |
| EP2799428B1 (en) | 2008-08-13 | 2016-11-16 | Metabasis Therapeutics, Inc. | Glucagon antagonists |
| BR112013016033A2 (en) | 2010-12-23 | 2018-06-05 | Pfizer | glucagon receptor modulators |
| ES2597972T3 (en) | 2011-02-08 | 2017-01-24 | Pfizer Inc | Glucagon receptor modulator |
| ES2550345T3 (en) | 2011-07-22 | 2015-11-06 | Pfizer Inc. | Quinolinylglucagon receptor modulators |
| ES2702237T3 (en) * | 2011-12-21 | 2019-02-28 | Allergan Inc | Compounds that act on multiple prostaglandin receptors that give a general anti-inflammatory response |
| EP2897939B1 (en) | 2012-09-21 | 2017-02-01 | Sanofi | Benzoimidazole-carboxylic acid amide derivatives for treating metabolic or cardiovascular diseases |
| US9649294B2 (en) | 2013-11-04 | 2017-05-16 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
| WO2015191900A1 (en) | 2014-06-12 | 2015-12-17 | Ligand Pharmaceuticals, Inc. | Glucagon antagonists |
| CN107311933B (en) * | 2017-06-28 | 2020-12-22 | 中国人民解放军军事医学科学院毒物药物研究所 | Benzimidazole derivative, preparation method and application thereof |
| WO2019160940A1 (en) | 2018-02-13 | 2019-08-22 | Ligand Pharmaceuticals Incorporated | Glucagon receptor antagonists |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000059889A1 (en) * | 1999-04-06 | 2000-10-12 | Sankyo Company, Limited | α-SUBSTITUTED CARBOXYLIC ACID DERIVATIVES |
-
2002
- 2002-12-10 WO PCT/DK2002/000832 patent/WO2003053938A1/en not_active Application Discontinuation
- 2002-12-10 AU AU2002347022A patent/AU2002347022A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003053938A1 (en) | 2003-07-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2002347022A1 (en) | Benzimidazols and indols as glucagon receptor antagonists/inverse agonisten | |
| AU2002314433A1 (en) | Ephrin-tie receptor materials and methods | |
| AU2002365622A1 (en) | Novel glucagon antagonists | |
| AU2001255798A1 (en) | Glucagon antagonists | |
| AU2002341834A1 (en) | Antagonists | |
| AU2003233780A1 (en) | Novel glucagon antagonists/inverse agonists | |
| AU2002367424A1 (en) | Androgen receptor antagonists | |
| AU2003236205A1 (en) | Glucagon antagonists/inverse agonists | |
| AUPR769501A0 (en) | Cytokine receptor 1 | |
| AU2002223501A1 (en) | Glucagon antagonists/inverse agonists | |
| IL152700A0 (en) | Substituted 1-aminoalkyl-lactams and their use as muscarinc receptor antagonists | |
| AU2001273032A1 (en) | Cytokine receptor zcytor17 | |
| AU2002223500A1 (en) | Glucagon antagonists/inverse agonists | |
| AU2001264657A1 (en) | Crf receptor antagonists | |
| AU2003255501A1 (en) | Cxcr4 receptor antagonists | |
| AU2002252460A1 (en) | Human cytokine receptor | |
| AU2003291959A1 (en) | Novel glucagon antagonists | |
| AU2002351730A1 (en) | Glucagon receptor antagonists/inverse agonists | |
| HRP20031096A2 (en) | 2,5-diarylpyrazines, 2,5-diarylpyridines and 2,5-diarylpyrimidines as crf1 receptor modulators | |
| AU2002365655A1 (en) | 5-ht7 receptor antagonists | |
| AU2002305944A1 (en) | Mouse cytokine receptor | |
| AU2003225054A1 (en) | Toll-like receptor 11 and toll-like receptor 12 | |
| AU2002359524A1 (en) | P2x7 receptor antagonists | |
| AU2003206014A1 (en) | Neuropeptide receptor and uses thereof | |
| AU2001277980A1 (en) | Human cytokine receptor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |